BRAINSWAY LTD/S (NASDAQ:BWAY) Given Average Recommendation of “Buy” by Brokerages

Share on StockTwits

Shares of BRAINSWAY LTD/S (NASDAQ:BWAY) have been assigned an average rating of “Buy” from the six analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $16.75.

A number of brokerages have recently commented on BWAY. Oppenheimer lifted their price target on shares of Novavax from $1.25 to $25.00 in a report on Monday, May 13th. Zacks Investment Research upgraded shares of Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Tuesday. LADENBURG THALM/SH SH lowered shares of PennantPark Investment from a “buy” rating to a “neutral” rating in a report on Monday, May 13th. CIBC lifted their price target on shares of NorthWest Health Prop Real Est Inv Trust from C$11.75 to C$12.00 in a report on Monday, May 13th. Finally, Cantor Fitzgerald started coverage on shares of CytomX Therapeutics in a report on Monday, May 13th. They issued an “overweight” rating and a $21.00 target price on the stock.

Shares of NASDAQ:BWAY traded up $0.03 during mid-day trading on Monday, reaching $10.18. 2,131 shares of the company’s stock were exchanged, compared to its average volume of 9,311. The firm’s fifty day simple moving average is $9.95. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.33 and a current ratio of 1.33. BRAINSWAY LTD/S has a twelve month low of $8.00 and a twelve month high of $12.39.

BRAINSWAY LTD/S (NASDAQ:BWAY) last issued its quarterly earnings results on Wednesday, May 29th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. The business had revenue of $5.18 million for the quarter, compared to analyst estimates of $5.00 million. Sell-side analysts forecast that BRAINSWAY LTD/S will post -0.43 EPS for the current year.


Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.

Read More: How does a security become overbought?

Analyst Recommendations for BRAINSWAY LTD/S (NASDAQ:BWAY)

Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with's FREE daily email newsletter.